Mesoblast (MESO) Debt Ratio (2018 - 2026)

Mesoblast (MESO) posted Debt Ratio of 0.11 for Q4 2025, down 136.12% sequentially from 0.29 in Q2 2025, and down 81.13% YoY from 0.56 in Q4 2024.

Analysis

Mesoblast (MESO) Debt Ratio (2018 - 2026) Analysis & Trends

Mesoblast has reported Debt Ratio for 8 years, with the latest figure at 0.11 in Q4 2025.

Quarterly Debt Ratio fell 81.13% year-over-year to 0.11 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.11 (down 81.13% YoY) and the FY2025 annual result came in at 0.29, up 71.0% from the prior year.
Debt Ratio fell to 0.11 in Q4 2025 per MESO's latest filing, from 0.29 in the prior quarter.
Over five years, Debt Ratio peaked at 0.29 in Q2 2025 and troughed at 0.11 in Q4 2025.
A 5-year average of 0.11 and a median of 0.13 in 2021 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2024: Debt Ratio jumped 365.74% in 2022, then slumped 147.81% in 2024.
Over 5 years, Debt Ratio stood at 0.25 in 2021, then plunged by 111.41% to 0.03 in 2022, then grew by 16.12% to 0.02 in 2023, then plunged by 147.81% to 0.06 in 2024, then tumbled by 81.13% to 0.11 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.11, 0.29, and 0.06 for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Mesoblast	2.24 Bn	2.14 Bn	-	0.01

Historic Data

Download Data